1. Tobramycin is a suppressor of premature termination codons.
- Author
-
Altamura, Nicola, Castaldo, Rosa, Finotti, Alessia, Breveglieri, Giulia, Salvatori, Francesca, Zuccato, Cristina, Gambari, Roberto, Panin, Giulia Chiara, and Borgatti, Monica
- Subjects
- *
TOBRAMYCIN , *MOLECULAR genetics , *GENETIC disorders , *IMMUNOSUPPRESSION , *CYSTIC fibrosis , *AMINOGLYCOSIDES , *PATIENTS - Abstract
Abstract: Premature translation terminations (PTCs) constitute the molecular basis of many genetic diseases, including cystic fibrosis, as they lead to the synthesis of truncated non-functional or partially functional protein. Suppression of translation terminations at PTCs (read-through) has been developed as a therapeutic strategy to restore full-length protein in several genetic diseases. Phenotypic consequences of PTCs can be exacerbated by the nonsense-mediated mRNA decay (NMD) pathway that detects and degrades mRNA containing PTC. Modulation of NMD, therefore, is also of interest as a potential target for the suppression therapy. Tobramycin is an aminoglycoside antibiotic, normally used to treat Pseudomonas aeruginosa pulmonary infection in CF patients. In the present study, by using yeast as a genetic system, we have examined the ability of Tobramycin to suppress PTCs as a function of the presence or absence of NMD. Results demonstrate that Tobramycin exhibits read-through ability on PTCs and preferentially in absence of NMD. [Copyright &y& Elsevier]
- Published
- 2013
- Full Text
- View/download PDF